Company research
Insight Molecular Diagnostics Inc.
CIK 1642380Updated Nov 20, 2026
IMDX price & chart
Loading TradingView…
NASDAQ:IMDX on TradingView ↗In the news
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio ↗
Recent filings
4 filing
4 filing
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
424B5 filing
424B5 filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure · Other Events
Items 2.02, 7.01, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 43,937,000Source | 70,216,000Source | 29,443,000Source | 50,517,000Source | 74,720,000Source | 40,427,000Source | 60,360,000Source | 70,973,000Source | 25,756,000Source | 35,081,000Source | 74,892,000Source | 100,091,000Source |
| Property, Plant and Equipment, NetUSD | 5,802,000Source | 6,193,000Source | 6,004,000Source | 6,410,000Source | 5,579,000Source | 8,911,000Source | 6,795,000Source | 5,404,000Source | 9,250,000Source | 5,984,000Source | 4,710,000Source | 8,711,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 14,600,000Source | 56,529,000Source | — | 14,600,000Source | 56,551,000Source | — | 14,600,000Source | 56,573,000Source | 0Source | 14,607,000Source | 56,595,000Source | 61,633,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 18,692,000Source | 3,363,000Source | 17,756,000Source | 24,287,000Source | 9,256,000Source | 28,201,000Source | 31,029,000Source | 5,578,000Source | 11,583,000Source | 8,636,000Source | 9,432,000Source | 19,993,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 258,000Source | 209,000Source | 192,000Source | 512,000Source | 85,000Source | 157,000Source | 3,540,000Source | 161,000Source | 1,128,000Source | 1,613,000Source | 484,000Source | 2,012,000Source |
| Inventory, NetUSD | 471,000Source | 232,000Source | 207,000Source | 693,000Source | — | 382,000Source | 459,000Source | — | 446,000Source | 410,000Source | — | — |
| Assets, CurrentUSD | 21,389,000Source | 4,793,000Source | 20,543,000Source | 26,842,000Source | 9,968,000Source | 30,517,000Source | 36,263,000Source | 6,535,000Source | 15,306,000Source | 11,759,000Source | 10,698,000Source | 25,536,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,239,000Source | 627,000Source | 1,659,000Source | 1,350,000Source | 595,000Source | 1,048,000Source | 1,235,000Source | 735,000Source | 1,420,000Source | 821,000Source | 643,000Source | 977,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | — | — | — | — | 3,499,000Source |
| Other Assets, NoncurrentUSD | 672,000Source | 699,000Source | 556,000Source | 702,000Source | 563,000Source | 574,000Source | 642,000Source | 438,000Source | 593,000Source | 691,000Source | 463,000Source | 371,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 53,133,000Source | 60,505,000Source | 50,742,000Source | 49,419,000Source | 52,017,000Source | 51,118,000Source | 50,142,000Source | 54,053,000Source | 57,220,000Source | 47,355,000Source | 49,298,000Source | 60,497,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | 0Source | — | — | 0Source | — | — | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 368,524,000Source | 326,682,000Source | 394,945,000Source | 367,965,000Source | 326,201,000Source | 394,289,000Source | 367,387,000Source | 310,553,000Source | 369,211,000Source | 338,244,000Source | 310,295,000Source | 294,929,000Source |
| Retained Earnings (Accumulated Deficit)USD | -377,806,000Source | -317,028,000Source | -416,311,000Source | -366,952,000Source | -303,535,000Source | -405,051,000Source | -357,210,000Source | -299,005,000Source | -400,761,000Source | -350,539,000Source | -289,876,000Source | -260,676,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 86,000Source | 57,000Source | 67,000Source | 85,000Source | 37,000Source | 71,000Source | 41,000Source | 40,000Source | 86,000Source | 21,000Source | 49,000Source | 39,000Source |
| Stockholders' Equity Attributable to ParentUSD | -9,196,000Source | 9,711,000Source | -21,299,000Source | 1,098,000Source | 22,703,000Source | -10,691,000Source | 10,218,000Source | 11,588,000Source | -31,464,000Source | -12,274,000Source | 20,468,000Source | 34,292,000Source |
| Liabilities and EquityUSD | 43,937,000Source | 70,216,000Source | 29,443,000Source | 50,517,000Source | 74,720,000Source | 40,427,000Source | 60,360,000Source | 70,973,000Source | 25,756,000Source | 35,081,000Source | 74,892,000Source | 100,091,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 7,660,000Source | 9,090,000Source | 10,286,000Source | 6,652,000Source | 7,198,000Source | 12,005,000Source | 9,683,000Source | 8,327,000Source | 12,075,000Source | 7,275,000Source | 7,194,000Source | 12,106,000Source |
| Accounts Payable, CurrentUSD | 1,056,000Source | 872,000Source | 1,871,000Source | 1,277,000Source | 1,051,000Source | 1,615,000Source | 2,279,000Source | 908,000Source | 2,544,000Source | 2,279,000Source | 953,000Source | 1,253,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 2,228,000Source | 1,906,000Source | 1,904,000Source | 1,459,000Source | 1,309,000Source | 3,333,000Source | 2,524,000Source | 2,427,000Source | 2,461,000Source | 1,939,000Source | 1,649,000Source | 1,771,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 584,000Source | 340,000Source | 665,000Source | 559,000Source | 631,000Source | 491,000Source | 2,197,000Source | 1,564,000Source | 1,592,000Source | 1,500,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 615,000Source | 473,000Source | 2,219,000Source | 1,753,000Source | 2,760,000Source | 10,042,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -971,000Source | 1,927,000Source | -485,000Source | 1,129,000Source | -109,000Source | 575,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -64,000Source | 49,000Source | 36,000Source | 410,000Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -7,639,000Source | -5,839,000Source | -22,184,000Source | -20,713,000Source | -23,325,000Source | -45,568,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -613,000Source | -307,000Source | -3,185,000Source | -512,000Source | -932,000Source | -4,340,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 613,000Source | 307,000Source | 3,185,000Source | 516,000Source | 281,000Source | 4,340,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | 72,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 24,698,000Source | 28,558,000Source | 28,072,000Source | 20,429,000Source | 12,186,000Source | 35,806,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 16,436,000Source | 22,393,000Source | 2,583,000Source | -796,000Source | -12,071,000Source | -14,102,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | — | — | — | 23,203,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 19,000Source | 24,000Source | 91,000Source | 42,000Source | — | 24,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 521,000Source | 450,000Source | 661,000Source | 504,000Source | 615,000Source | 473,000Source | 2,219,000Source | 1,753,000Source | 2,760,000Source | 10,042,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | — | — | — | 12,000Source |
| Amortization of Intangible AssetsUSD | — | — | 0Source | 22,000Source | — | — | 0Source | 7,000Source | 7,000Source | 88,000Source | 88,000Source | 3,692,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | — | — | — | 1,528,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | — | — | — | — | — | — | — | — | -1,521,000Source | — |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | 5,000Source | -39,000Source | -185,000Source | — | — | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | 0Source | 0Source | -169,000Source | -1,283,000Source | — |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | -169,000Source | -1,283,000Source | — |
| General and Administrative ExpenseUSD | — | — | 2,545,000Source | 2,565,000Source | 2,873,000Source | 2,647,000Source | 2,991,000Source | 3,115,000Source | 10,633,000Source | 10,204,000Source | 11,182,000Source | 21,881,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 18,684,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | 14,600,000Source | 41,900,000Source | 6,757,000Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -10,854,000Source | -13,493,000Source | -11,260,000Source | -9,742,000Source | -4,290,000Source | -6,671,000Source | -50,222,000Source | -60,663,000Source | — | -18,612,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -2,926,000Source | -54,290,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | — | — | 139,000Source | — |
| Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | — | — | — | — | — | — | — | 0Source | -61,000Source | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | -471,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -10,854,000Source | -13,493,000Source | -11,260,000Source | -9,742,000Source | -4,290,000Source | -6,671,000Source | -50,222,000Source | -60,663,000Source | -27,781,000Source | -72,902,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -10,854,000Source | -13,493,000Source | — | -9,742,000Source | — | -6,671,000Source | -50,222,000Source | -60,926,000Source | -28,723,000Source | -73,422,000Source |
| Nonoperating Income (Expense)USD | — | — | 194,000Source | 22,000Source | 142,000Source | 100,000Source | 123,000Source | 128,000Source | 902,000Source | 378,000Source | 281,000Source | -615,000Source |
| Operating ExpensesUSD | — | — | 11,187,000Source | 13,565,000Source | 11,559,000Source | 10,180,000Source | 4,428,000Source | 8,124,000Source | 53,422,000Source | 61,781,000Source | 25,549,000Source | 17,979,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 223,000Source | 53,000Source | 162,000Source | 125,000Source | 146,000Source | 157,000Source | 1,011,000Source | 462,000Source | 394,000Source | -67,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 26,024,000Source | 29,143,000Source | 29,143,000Source | 26,012,000Source | 13,848,000Source | 32,812,000Source |
| Depreciation, Depletion and Amortization, Nonproduction | — | — | —Source | —Source | — | — | —Source | —Source | — | — | — | — |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 260,000Source | 115,000Source | 239,000Source | 518,000Source | 32,000Source | 2,138,000Source | 4,055,000Source | 1,881,000Source | 1,503,000Source | 958,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | -11,048,000Source | -13,515,000Source | -11,402,000Source | -9,842,000Source | -4,413,000Source | -6,799,000Source | -51,124,000Source | -61,041,000Source | -25,136,000Source | -17,997,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 223,000Source | 53,000Source | 162,000Source | 125,000Source | 146,000Source | 157,000Source | 1,011,000Source | 462,000Source | 394,000Source | -67,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | -13,493,000Source | — | — | — | — | — | -60,663,000Source | -24,855,000Source | -18,612,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -10,854,000Source | -13,493,000Source | -11,260,000Source | -9,742,000Source | -4,290,000Source | -6,671,000Source | -50,222,000Source | -60,663,000Source | -27,781,000Source | -72,902,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.34Source | -0.98Source | -0.31Source | -0.3Source | -0.12Source | -0.26Source | -1.65Source | -4.66Source | -3.75Source | -0.66Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.34Source | -0.98Source | -0.31Source | -0.3Source | -0.12Source | -0.26Source | -1.65Source | -4.66Source | -3.75Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 32,033,000Source | 13,714,000Source | 36,750,000Source | 32,023,000Source | 34,519,000Source | 25,694,000Source | 30,476,000Source | 13,071,000Source | 7,651,000Source | 110,800Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 32,033,000Source | 13,714,000Source | 36,750,000Source | 32,023,000Source | 34,519,000Source | 25,694,000Source | 30,476,000Source | 13,071,000Source | 7,651,000Source | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 0Source | 22,000Source | — | — | 0Source | 7,000Source | 7,000Source | 88,000Source | 88,000Source | 3,692,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 584,000Source | 318,000Source | — | — | 631,000Source | 484,000Source | 2,190,000Source | 1,476,000Source | 1,592,000Source | 1,500,000Source |
| General and Administrative ExpenseUSD | — | — | 2,545,000Source | 2,565,000Source | 2,873,000Source | 2,647,000Source | 2,991,000Source | 3,115,000Source | 10,633,000Source | 10,204,000Source | 11,182,000Source | 21,881,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 18,684,000Source |
| Gross ProfitUSD | — | — | 139,000Source | 50,000Source | 157,000Source | 338,000Source | 15,000Source | 1,325,000Source | 2,298,000Source | 740,000Source | 413,000Source | -18,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -10,854,000Source | -13,493,000Source | -11,260,000Source | -9,742,000Source | -4,290,000Source | -6,671,000Source | -50,222,000Source | -60,663,000Source | — | -18,612,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | -0.98Source | — | — | — | — | — | -4.66Source | -3.37Source | -0.17Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | -0.98Source | — | — | — | — | — | -4.66Source | -3.37Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -2,926,000Source | -54,290,000Source |
| Interest Income (Expense), NetUSD | — | — | -29,000Source | -31,000Source | -20,000Source | -25,000Source | -23,000Source | -29,000Source | -109,000Source | -84,000Source | -52,000Source | -77,000Source |
| Marketing and Advertising ExpenseUSD | — | — | 97,000Source | 41,000Source | 262,000Source | 159,000Source | 135,000Source | 65,000Source | 582,000Source | 257,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -10,854,000Source | -13,493,000Source | — | -9,742,000Source | — | -6,671,000Source | -50,222,000Source | -60,926,000Source | -28,723,000Source | -73,422,000Source |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, BasicUSD | — | — | — | -13,493,000Source | — | — | — | — | — | -60,926,000Source | -25,797,000Source | — |
| Nonoperating Income (Expense)USD | — | — | 194,000Source | 22,000Source | 142,000Source | 100,000Source | 123,000Source | 128,000Source | 902,000Source | 378,000Source | 281,000Source | -615,000Source |
| Operating ExpensesUSD | — | — | 11,187,000Source | 13,565,000Source | 11,559,000Source | 10,180,000Source | 4,428,000Source | 8,124,000Source | 53,422,000Source | 61,781,000Source | 25,549,000Source | 17,979,000Source |
| Research and Development ExpenseUSD | — | — | 3,878,000Source | 2,817,000Source | 4,486,000Source | 3,269,000Source | 4,953,000Source | 2,924,000Source | 15,900,000Source | 9,839,000Source | 9,294,000Source | 7,301,000Source |
| Selling and Marketing ExpenseUSD | — | — | 1,386,000Source | 1,043,000Source | 1,916,000Source | 1,460,000Source | 2,402,000Source | 1,206,000Source | 6,343,000Source | 3,944,000Source | 2,795,000Source | 1,132,000Source |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Filing attachments
ex4-1.htm · 8-K · 2026-11-18
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Insight Molecular Diagnostics INC. Warrant Shares: Initial Exercise Date: November _______ 18, 2026 ──────────────────────────────────────────────────────── THIS COMMON STOCK PURCHASE WARRANT (the “ Warrant ”) certifies that, for value received, _____________ or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on …
Read attachment ↗ex99-1.htm · 8-K · 2026-11-18
Exhibit 99.1 Insight Molecular Diagnostics Announces Proposed Public Offering NASHVILLE, Tenn. - November 16, 2026 - Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,” “us,” “our,” or the “Company”) today announced that it has commenced an underwritten public offering of shares of its common stock, or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, the Company intends to grant the underwriter a 30-day option …
Read attachment ↗ex99-2.htm · 8-K · 2026-11-18
Exhibit 99.2 Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering NASHVILLE, Tenn. - November 17, 2026 - Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,” “us,” “our,” or the “Company”) today announced the pricing of its underwritten public offering of 8,296,429 shares of its common stock at a price to the public of $1.75 per share and pre-funded warrants to purchase up to 275,000 shares of common stock at a price to the public of $1.7499 per pre-funded…
Read attachment ↗ex99-1.htm · 8-K · 2026-11-16
Exhibit 99.1 IMDx Reports Third Quarter 2026 Results and Provides Corporate Update Progress with FDA review of GraftAssureDx and its planned response to FDA’s request for additional information Initiated enrollment into GALACTIC registry study from UCLA Medical Center Revenue from GraftAssureCore lab-developed test expected to build as GALACTIC enrollment grows Q3 2026 revenue of $559,000; operating expenses decline as FDA-submission costs wind down iMDx appoints vete…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-10
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx Discussions with FDA advance toward expected marketing authorization for GraftAssureDx FDA completes current portion of substantive review in a timely manner Favorable Medicare reimbursement policy issued in July significantly increases GraftAssureDx surveillance testing opportunity Strong head-to-head data drive kitted customer interest N…
Read attachment ↗ex107.htm · S-8 · 2026-07-24
Calculation of Filing Fee Tables S-8 Insight Molecular Diagnostics Inc. ────────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ───────────────────────────────────────────…
Read attachment ↗